Given the extent of bone loss caused by radiation, chemotherapy, and tumor-targeted therapies, there has been natural interest in the efficacy of PTH and PTHrP analogs in the oncology setting to mitigate low bone mass and prevent fractures in patients with bone metastatic disease. The gene discussed is PTHLH; the disease is neoplasm.